A 28-year-old woman from Delhi presents with primary infertility of 3 years duration. She has regular menstrual cycles (28–30 days), normal BMI (22 kg/m²), and unremarkable physical examination. Her husband's semen analysis is normal. Transvaginal ultrasound shows normal ovarian volume and morphology. Serum FSH, LH, and prolactin are normal. Progesterone level on day 21 of the cycle is 2 ng/mL (normal luteal phase >5 ng/mL). What is the most appropriate first-line ovulation induction agent for this patient?

Explanation

## Clinical Scenario Analysis This patient has **anovulation with normal hormonal profile and normal ovarian anatomy**—a presentation consistent with **World Health Organization (WHO) Group II anovulation** (normogonadotropic, normoestrogenic). The low progesterone on day 21 confirms absent or inadequate ovulation despite regular menstrual-like cycles (anovulatory cycles). ## First-Line Agent Selection **Key Point:** Clomiphene citrate is the gold-standard first-line ovulation induction agent for WHO Group II anovulation in the absence of PCOS or other contraindications. ### Why Clomiphene Citrate? 1. **Mechanism:** Selective estrogen receptor modulator (SERM) that blocks negative feedback of estrogen on the hypothalamus and pituitary, triggering endogenous FSH and LH secretion. 2. **Cost-effective:** Oral agent, inexpensive, no need for monitoring injections. 3. **Safety profile:** Low risk of ovarian hyperstimulation syndrome (OHSS) compared to gonadotropins. 4. **Efficacy:** 70–80% ovulation rate; 40–50% pregnancy rate in WHO Group II anovulation. 5. **First-line status:** Endorsed by ASRM and ICMR guidelines as initial therapy. **High-Yield:** Standard dosing is 50 mg daily for 5 days starting from day 3 of the menstrual cycle (or day 2–5). If no ovulation occurs, dose can be escalated to 100 mg or 150 mg in subsequent cycles. ## Monitoring During Clomiphene Therapy - Transvaginal ultrasound on day 10–12 to assess follicle development (target: dominant follicle ≥18 mm). - Serum estradiol and LH surge detection (optional, depending on protocol). - Timed intercourse or IUI when follicle is mature. **Clinical Pearl:** Clomiphene-resistant anovulation (failure to ovulate after 150 mg daily × 5 days) occurs in ~20% of patients and mandates escalation to gonadotropins or letrozole. ## Why Not the Other Agents in This Case? | Agent | Indication | Why Not First-Line Here | |-------|-----------|------------------------| | Letrozole | PCOS, clomiphene resistance, endometrial thickening risk | Comparable efficacy to clomiphene in WHO Group II, but clomiphene is traditional first-line; letrozole is second-line or preferred in PCOS. | | Gonadotropins + GnRH agonist | Hypogonadotropic hypogonadism, clomiphene resistance, IVF | Requires daily injections, frequent monitoring, higher OHSS risk; reserved for second-line or when IVF planned. | | Metformin | PCOS with insulin resistance | No insulin resistance documented; metformin is adjunct in PCOS, not primary therapy for non-PCOS anovulation. |